Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Myelodysplastic Syndromes

San Diego, CA—A phase 2 expansion-cohort clinical trial has shown encouraging results with the combination of oral rigosertib, a novel styryl benzyl sulfone, and azacitidine (Vidaza) in patients with heavily pretreated myelodysplastic syndromes (MDS) compared with azacitidine monotherapy, according to data presented at ASH 2018.

Results 1 - 1 of 1